Andersen MH - Search Results

1

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.

Becker JC, Andersen MH, Hofmeister-Müller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kämpgen E, Opitz A, Zapatka M, Bröcker EB, Thor Straten P, Schrama D, Ugurel S. Becker JC, et al. Among authors: andersen mh. Cancer Immunol Immunother. 2012 Nov;61(11):2091-103. doi: 10.1007/s00262-012-1266-9. Epub 2012 May 8. Cancer Immunol Immunother. 2012. PMID: 22565484 Free PMC article. Clinical Trial.

2

Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients.

Schrama D, Andersen MH, Terheyden P, Schrøder L, Pedersen LO, thor Straten P, Becker JC. Schrama D, et al. Among authors: andersen mh. Cancer Res. 2001 Jan 15;61(2):493-6. Cancer Res. 2001. PMID: 11212239

3

Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.

Andersen MH, Pedersen LO, Becker JC, Straten PT. Andersen MH, et al. Cancer Res. 2001 Feb 1;61(3):869-72. Cancer Res. 2001. PMID: 11221872

4

In situ cytokine therapy: redistribution of clonally expanded T cells.

thor Straten P, Guldberg P, Schrama D, Andersen MH, Moerch U, Seremet T, Siedel C, Reisfeld RA, Becker JC. thor Straten P, et al. Among authors: andersen mh. Eur J Immunol. 2001 Jan;31(1):250-8. doi: 10.1002/1521-4141(200101)31:1<250::AID-IMMU250>3.0.CO;2-8. Eur J Immunol. 2001. PMID: 11265641 Free article.

5

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Andersen MH, et al. Cancer Res. 2001 Aug 15;61(16):5964-8. Cancer Res. 2001. PMID: 11507035

6

Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.

Andersen MH, Keikavoussi P, Bröcker EB, Schuler-Thurner B, Jonassen M, Søndergaard I, Straten PT, Becker JC, Kämpgen E. Andersen MH, et al. Int J Cancer. 2001 Dec 15;94(6):820-4. doi: 10.1002/ijc.1536. Int J Cancer. 2001. PMID: 11745484 Free article.

7

Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report.

Pedersen LØ, Vetter CS, Mingari MC, Andersen MH, thor Straten P, Bröcker EB, Becker JC. Pedersen LØ, et al. Among authors: andersen mh. J Invest Dermatol. 2002 Apr;118(4):595-9. doi: 10.1046/j.1523-1747.2002.01698.x. J Invest Dermatol. 2002. PMID: 11918704 Free article.

8

Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells.

Schrama D, Pedersen LØ, Keikavoussi P, Andersen MH, Straten Pt Pt, Bröcker EB, Kämpgen E, Becker JC. Schrama D, et al. Among authors: andersen mh. J Invest Dermatol. 2002 Dec;119(6):1443-8. doi: 10.1046/j.1523-1747.2002.19604.x. J Invest Dermatol. 2002. PMID: 12485452 Free article.

9

Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression.

Terheyden P, Schrama D, Pedersen LØ, Andersen MH, Kämpgen E, thor Straten P, Becker JC. Terheyden P, et al. Among authors: andersen mh. Scand J Immunol. 2003 Nov;58(5):566-71. doi: 10.1046/j.1365-3083.2003.01324.x. Scand J Immunol. 2003. PMID: 14629628 Free article.

10

HLA-B35-restricted immune responses against survivin in cancer patients.

Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. Reker S, et al. Among authors: andersen mh. Int J Cancer. 2004 Mar 1;108(6):937-41. doi: 10.1002/ijc.11634. Int J Cancer. 2004. PMID: 14712500 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

379 results

Search Page